Read the latest RCOphth news updates and guidance here.
Allergan Pharmaceuticals Ireland is recalling numerous batches of Ozurdex due to the possibility that a single loose silicone particle of approximately 300 microns in diameter may become detached from the needle sleeve during administration of the implant and may be delivered into the eye along with the implant.
The College has received queries from members to clarify whether there is a specific cut off for glycaemic control, either measured via HbA1C or a blood glucose level on the day, beyond which it is unsafe to proceed with cataract surgery.
There are a range of cefuroxime preparations currently in use for the prevention of endophthalmitis in intraocular surgery. The College recommends that for those using a non licensed product, users should check the SmPCs and avoid use of any product which specifically cautions against intraocular use.
The NHS Improvement national patient safety team have informed the College of the continued trend of incidents involving issues with detachment of cannulas during ophthalmic surgery (cannula-associated ocular injury, COI). The cannula is usually attached to either a saline or a viscoelastic syringe. The combination of a small lumen and plunger pressure can result in significant hydraulic force. If the cannula does detach, it can cause extensive damage to the globe with resultant visual impairment.
This research, conducted through the British Ophthalmological Surveillance Unit (BOSU), found patients suffering permanent and severe visual loss due to health service initiated delays1. The research involving all UK consultant ophthalmologists, showed that up to 22 patients per month may be losing vision by such delays. These patients are from a vulnerable social group with chronic conditions requiring long-term routine follow-up such as glaucoma, age related macular degeneration and diabetic retinopathy.
The College recognises that botulinum toxin and surgical treatment for strabismus* are important procedures that are performed in children and adults to promote, improve or re-establish binocular function, manage diplopia and restore ocular alignment and balance. Surgical intervention (including botulinum toxin injections) performed to achieve these aims is thus not a cosmetic procedure and does not fall under the GMC guidance for cosmetic surgery. Commissioning pathways for the management of squints reflect this. Surgical intervention (including botulinum toxin injections) performed to achieve these aims is thus not a cosmetic procedure and does not fall under the GMC guidance for cosmetic surgery. Commissioning pathways for the management of squints reflect this.
These guidelines (July 2015) reflect changes in treatments, since the 2010 Interim RVO Guidelines. The guidelines provide evidence-based, clinical advice for the management of different aspects of RVO. The scope is limited to current diagnostic tools, management and service set-up and delivery to facilitate delivery of optimal care.
It is hoped that the Guidelines for Thyroid Eye Disease (2015) will facilitate early diagnosis and better treatment of patients with this disease. It is estimated that there are about 2,500 new cases of Thyroid Eye Disease (TED) every year in the UK. The figures have declined over the past 10-20 years for reasons that are unclear.
The Royal College of Ophthalmologists welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend 125 micrograms Ocriplasmin intravitreal injection as an option for the treatment of vitreomacular traction (VMT) in adults who have either stage II full-thickness macular holes (FTMH) with a diameter of ≤ 400um and/or severe symptoms.
MSD has informed the Royal College of Ophthalmologists that there are now a limited number of preservative-free (PF) Trusopt® (dorzolamide hydrochloride) eye drops presently available in the UK. In light of this and the fact that it is a limited supply, The College would like to advise you of the recommended best use of this medication.
